

Resource Summary Report

Generated by [RRID](#) on Aug 3, 2026

Monoclonal Anti-Cytokeratin, pan antibody produced in mouse

RRID:AB_2134432

Type: Antibody

Proper Citation

Sigma-Aldrich Cat# C5992, RRID:AB_2134432

Antibody Information

URL: http://antibodyregistry.org/AB_2134432

Proper Citation: Sigma-Aldrich Cat# C5992, RRID:AB_2134432

Target Antigen: Cytokeratin pan antibody produced in mouse

Host Organism: mouse

Clonality: monoclonal

Comments: Vendor recommendations: IgG1 dot blot: suitable, immunocytochemistry: suitable, immunoblotting: suitable, immunohistochemistry: 10-20 mug/mL; Immunocytochemistry; Immunohistochemistry; Western Blot; Other

Antibody Name: Monoclonal Anti-Cytokeratin, pan antibody produced in mouse

Description: This monoclonal targets Cytokeratin pan antibody produced in mouse

Target Organism: chicken, feline, rat, hamster, snake, porcine, canine, goat, reptile, pig, mouse, carp, chickenbird, zebrafishfish, rabbit, bovine, lizard, human, sheep

Antibody ID: AB_2134432

Vendor: Sigma-Aldrich

Catalog Number: C5992

Record Creation Time: 20250819T233803+0000

Record Last Update: 20250820T055631+0000

Ratings and Alerts

No rating or validation information has been found for Monoclonal Anti-Cytokeratin, pan antibody produced in mouse.

No alerts have been found for Monoclonal Anti-Cytokeratin, pan antibody produced in mouse.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Ma D, et al. (2025) Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer. *Cancer cell*, 43(6), 1061.

Stupichev D, et al. (2025) AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinoma. *Cell reports. Medicine*, 6(8), 102299.

Li Y, et al. (2024) Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite. *Cancer cell*, 42(6), 985.

Miheecheva N, et al. (2022) Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity. *Cell reports*, 40(7), 111180.

Veras FP, et al. (2022) Pyruvate kinase M2 mediates IL-17 signaling in keratinocytes driving psoriatic skin inflammation. *Cell reports*, 41(13), 111897.

Awad MM, et al. (2022) Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. *Cancer cell*, 40(9), 1010.